The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

• Status: Not yet recruiting
• Trial end date: 2023-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Herlev and Gentofte Hospital
• Treatments: Interleukin 1 Receptor Antagonist Protein

Criteria

Inclusion Criteria:

• Aged at least eighteen years old.

• Able to provide written informed consent.

• Have a medical diagnosis of nickel allergy with at least a +2 reaction on the

• ICDRG scoring system when challenged with nickel.

• Fitzpatrick skin type 1-4.

• Able to speak and understand Danish.

Exclusion Criteria:

• Received any topical immunomodulating or immunosuppresive treatment on the lower back two weeks prior, or applied crème/lotion on the lower back 24 hours prior to day 0.

• Received systemic immunomodulating or immunosuppressive treatment four weeks prior to day 0.

• Any skin lesions at the area of interest such as nevi, scar tissue or pigment changes.

• Dermatitis and/or infection.

• Recent (3 months or less) administration of a live virus vaccine.

• Women of childbearing potential who are not taking adequate contraception or who are pregnant, plan to become pregnant during the study duration or lactating.

• Taking part in any other intervention study.

• Has any other condition which would, in the Investigator's opinion, deem the patient unsuitable for participation in the study (e.g. condition requiring long term or frequent oral steroid use).

• Presence of any condition or use of any medication which precludes the use of the study drug.

• Allergy to any of the ingredients in the drug.